Evidence map›Paper›PMID 39799263›Full record

ArticleCommunications biology2025

Promoted read-through and mutation against pseudouridine-CMC by an evolved reverse transcriptase.

Zhiyong He, Weiqi Qiu, Huiqing Zhou

Abstract read
In one paragraph

Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Zhiyong HeDepartment of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, USA.ORCID http://orcid.org/0000-0001-7976-9928
Weiqi QiuDepartment of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, USA.
Huiqing ZhouDepartment of Chemistry, Merkert Chemistry Center, Boston College, Chestnut Hill, MA, USA. huiqing.zhou@bc.edu.ORCID http://orcid.org/0000-0002-9220-4742

Funding

INVESTIGATE SEQUENCE SPECIFICITY IN THE BIOSYNTHESIS AND RECOGNITION OF RNA CHEMICAL MODIFICATIONSR35GM150789 · NIGMS · BOSTON COLLEGE · PI Huiqing Zhou · 2023 to 2026
$1.6M
NIGMS NIH HHS R35 GM150789U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM150789
6 · The paper itself

Abstract

Pseudouridine (Ψ) is an abundant RNA chemical modification that plays critical biological functions. Current Ψ detection methods are limited in identifying Ψs at base-resolution in U-rich sequence contexts, where Ψ occurs frequently. Here we report "Mut-Ψ-seq" that utilizes the classic N-cyclohexyl N'-(2-morpholinoethyl)carbodiimide (CMC) agent and an evolved reverse transcriptase ("RT-1306") for Ψ mapping at base-resolution. CMC selectively labels Ψs in RNA forming the CMC-Ψ adduct and we show that RT-1306 presents promoted read-through and mutation against the CMC-Ψ. We report a high-confidence list of Ψ sites in polyA-enriched RNAs from HEK-293T cells identified by orthogonal chemical treatments (CMC and bisulfite). The mutation signatures resolve the position of Ψ in UU-containing sequences, revealing diverse occurrence of Ψs in such sequences. This work provides methods and datasets for biological research of Ψ, and expands the toolkit for epitranscriptomic studies by combining the reverse transcriptase engineering and selective chemical labeling strategies.

Indexed as

MutationPseudouridineRNA-Directed DNA PolymeraseHEK293 CellsHumansPseudouridineRNA-Directed DNA Polymerase

Identifiers

PMID39799263
PMCPMC11724883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.